Skip Navigation Links
Centers for Disease Control and Prevention
 CDC Home CDC HomeSearchHealth Topics A-Z
Travelers' Health
U.S. Department of Health and Human Services

Contents
 Destinations
 Outbreaks
 Diseases
 Vaccinations
 Insect/Arthropod Protection
 Safe Food and Water
 Travel Medicine Clinics
 Yellow Book 2003-2004
 Traveling with Children
 Special Needs Travelers
 Traveling with Pets
 Cruise Ships and Air Travel
 Illness and Injury Abroad
 Nonmedical Emergency Preparation
 Reference Materials
 Other Related Sites
 
 State and Local Health Departments
 Quarantine Stations
 Division of Global Migration and Quarantine
 GeoSentinel
Global Surveillance Network of ISTM & CDC
 National Center for Infectious Diseases
 USDA/APHIS 
Importing food, plant, animal products
 U.S. State Department
 Pan American Health Organization
 World Health Organization
The Yellow Book - Health Information for International Travel, 2003-2004
 
_

Rabies

Description

Rabies, an acute, fatal encephalomyelitis caused by neurotropic viruses in the family Rhabdoviridae, genus Lyssavirus, is almost always transmitted by an animal bite that inoculates the virus into wounds. Very rarely, rabies has been transmitted by nonbite exposures that introduce the virus into open wounds or mucous membranes. All mammals are believed to be susceptible, but reservoirs are carnivores and bats. Although dogs are the main reservoir in resource-poor countries, the epidemiology of the disease differs sufficiently from one region or country to another to warrant the medical evaluation of all mammal bites.

Occurrence

Rabies is found on all continents except Antarctica. In certain areas of the world, canine rabies remains highly endemic, including (but not limited to) parts of Brazil, Bolivia, Colombia, Ecuador, El Salvador, Guatemala, India, Mexico, Nepal, Peru, the Philippines, Sri Lanka, Thailand, and Vietnam. The disease is also found in dogs in most of the other countries of Africa, Asia, and Central and South America, except as noted in Table 3–13, which lists countries that have reported no cases of rabies during the most recent 2-year period for which information is available (formerly referred to as “rabies-free countries”).

Additional information can be obtained from the World Health Organization, local health authorities of the country, the embassy, or the local consulate's office in the United States.

Table 3–13. Countries and political units reporting no cases of rabies during 1999*
Region Countries
Africa Cape Verde, Libya, Mauritius, Réunion, São Tome and Principe, and Seychelles
Americas North: Bermuda, St. Pierre and Miquelon
Caribbean: Antigua and Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Guadeloupe, Jamaica, Martinique, Montserrat, Netherlands Antilles (Bonaire, Curaçao, Saba, Saint Eustatius, and Sint Maarten), Saint Kitts (Saint Christopher) and Nevis, Saint Lucia, Saint Martin, Saint Vincent and Grenadines, and Virgin Islands (UK and US)
South: Uruguay
Asia Armenia, Cyprus, Hong Kong, Japan, Kuwait, Lebanon, Qatar, and Singapore
Europe Albania, Finland, Gibraltar, Greece, Iceland, Ireland, Isle of Man, Italy, Malta, Norway (mainland), Portugal, Spain* (except Ceuta/Melilla), Sweden, Switzerland, and United Kingdom
Oceania† Australia,* Cook Islands, Fiji, French Polynesia, Guam, Hawaii, Kiribati, Micronesia, New Caledonia, New Zealand, Palau, Papua New Guinea, Samoa, and Vanuatu
* Bat rabies exists in some areas that are free of terrestrial rabies.
† Most of Pacific Oceania is reportedly rabies-free.

Risk for Travelers

Travelers to rabies-endemic countries should be warned about the risk of acquiring rabies, although rabies vaccination is not a requirement for entry into any country. Travelers with extensive unprotected outdoor, evening, and nighttime exposure in rural areas, such as might be experienced while bicycling, camping, or engaging in certain occupational activities, might be at high risk even if their trip is brief.

Clinical Description

The disease progresses from a nonspecific prodromal phase to paresis or paralysis; spasms of swallowing muscles can be stimulated by the sight, sound, or perception of water (hydrophobia); delirium and convulsions can develop, followed by coma and death.

Prevention

Preexposure vaccination with human diploid cell rabies vaccine (HDCV), purified chick embryo cell (PCEC) vaccine, or rabies vaccine adsorbed (RVA) may be recommended for international travelers based on the local incidence of rabies in the country to be visited, the availability of appropriate antirabies biologicals, and the intended activity and duration of stay of the traveler. Preexposure vaccination may be recommended for veterinarians, animal handlers, field biologists, spelunkers, missionaries, and certain laboratory workers. Table 3–14 provides criteria for preexposure vaccination. Preexposure vaccination does not eliminate the need for additional medical attention after a rabies exposure, but simplifies postexposure prophylaxis in populations at risk by eliminating the need for rabies immune globulin (RIG) and by decreasing the number of doses of vaccine required. Preexposure vaccination is of particular importance for travelers at risk of exposure to rabies in countries where locally available rabies vaccines might carry a high risk of adverse reactions. Preexposure vaccination can also provide protection when there is an unapparent or unrecognized exposure to rabies and when postexposure prophylaxis might be delayed.

Purified equine rabies immune globulin (ERIG) has been used effectively in developing countries where human rabies immune globulin (RIG) might not have been available. If necessary, such heterologous product is preferable to no RIG administration in human rabies postexposure prophylaxis. The incidence of adverse reactions after the use of these products has been low (0.8%–6.0%), and most of those that occurred were minor. However, such products are neither evaluated by U.S. standards nor regulated by the U.S. Food and Drug Administration, and their use cannot be unequivocally recommended at this time. In addition, unpurified antirabies serum of equine origin might still be used in some countries where neither human RIG nor ERIG are available. The use of this antirabies serum is associated with higher rates of serious adverse reactions, including anaphylaxis.

Travelers should be advised that any animal bite or scratch should receive prompt local treatment by thorough cleansing of the wound with copious amounts of soap and water and a povidone-iodine solution if available; this local treatment will significantly reduce the risk of rabies. Travelers who might have been exposed to rabies should be advised to always contact local health authorities immediately for advice about postexposure prophylaxis and should also contact their personal physician or state health department as soon as possible thereafter.

Tables 3–15 and 3–16 provide information on preexposure and postexposure prophylaxis. Routine serologic testing is not necessary for travelers who receive the recommended preeexposure or postexposure regimen with HDCV, PCEC, or RVA vaccines. Exposed travelers previously vaccinated with noncell culture vaccines should receive the complete postexposure regimen unless they have developed a laboratory-confirmed antibody response to the primary vaccination. Serologic testing is still recommended for travelers whose immune response might be diminished by drug therapy or by diseases. Rabies preexposure prophylaxis might not be indicated for travelers to the countries in Table 3–13, and postexposure prophylaxis is rarely necessary after exposures to terrestrial animals in these countries.

Table 3–14. Criteria for preexposure immunization for rabies
Risk Category Nature of Risk

Typical Populations

Preexposure regimen

Continuous

Virus present continuously, often in high concentrations
Specific exposures likely to go unrecognized
Bite, nonbite, or aerosol exposure

Rabies research laboratory workers,* rabies biologics production workers

Primary course: Serologic testing every 6 months; booster vaccination if antibody titer is below acceptable level†

Frequent

Exposure usually episodic with source recognized, but exposure might also be unrecognized
Bite, nonbite, or aerosol exposure possible

Rabies diagnostic laboratory workers*, spelunkers, veterinarians and staff, and animal control and wildlife workers in rabies-epizootic areas

Primary course: Serologic testing every 2 years; booster vaccination if antibody titer is below acceptable level†

Infrequent (greater than general population)

Exposure nearly always episodic with source recognized

Bite or nonbite exposure

Veterinarians, animal control and wildlife workers in areas with low rabies rates; veterinary students; and travelers visiting areas where rabies is enzootic and immediate access to appropriate medical care, including biologics, is limited.

Primary course: No serologic testing or booster vaccination

Rare (general population)

Exposure always episodic, with source recognized
Bite or nonbite exposure

U.S. population at large, including individuals in rabies-epizootic areas

No preexposure immunization necessary.

* Judgment of relative risk and extra monitoring of vaccination status of laboratory workers is the responsibility of the laboratory supervisor (see U.S. Department of Health and Human Service's Biosafety in Microbiological and Biomedical Laboratories, 1999).
† Preexposure booster immunization consists of one dose of human diploid cell [rabies] vaccine (HDCV), purified chick embryo cell (PCEC) vaccine, or rabies vaccine adsorbed (RVA), 1.0 mL dose, intramuscular (IM) (deltoid area). Minimum acceptable antibody level is complete virus neutralization at a 1:5 serum dilution by the rapid fluorescent focus inhibition test. A booster dose should be administered if titer falls below this level.

Table 3–15. Preexposure immunization for rabies*
Vaccine Dose (mL) No. of Doses Schedule (days) Route

HDCV†

1.0

3

0, 7, 21 or 28

Intramuscular

PCEC

1.0

3

0, 7, 21 or 28

Intramuscular

RVA

1.0

3

0, 7, 21 or 28

Intramuscular

* Patients who are immunosuppressed by disease or medications should postpone preexposure vaccinations and consider avoiding activities for which rabies preexposure prophylaxis is indicated. When this course is not possible, immunosuppressed persons who are at risk for rabies should have their antibody titers checked after vaccination.Thus, preexposure immunization of immunosuppressed travelers is not recommended.
† HDCV, human diploid cell vaccine; PCEC, purified chick embryo cell; RVA, rabies vaccine adsorbed.

Table 3–16. Postexposure immunization for rabies*
Immunization
Status
Vaccine/
Product
Dose No. of doses Schedule (days) Route

Not previously immunized

RIG†

20 IU/kg body weight

1

0

Infiltrated at bite site (if possible); remainder intramuscular.

HDCV
PCEC
RVA

1.0 mL

5

0, 3, 7, 14, 28

Intramuscular

Previously immunized‡

HDCV
PCEC
RVA§

1.0 mL

2

0, 3

Intramuscular

* All postexposure treatment should begin with immediate thorough cleansing of all wounds with soap and water.
† RIG, rabies immune globulin; HDCV, human diploid cell (rabies) vaccine; PCEC, purified chick embryo cell; RVA, rabies vaccine adsorbed.
‡ Preexposure immunization with HDCV, PCEC, or RVA; prior postexposure prophylaxis with HDCV, PCEC, or RVA; or persons previously immunized with any other type of rabies vaccine and a documented history of positive antibody response to the prior vaccination.
§ RIG should not be administered.

Adverse Reactions

Travelers should be advised that they can experience local reactions such as pain, erythema, and swelling or itching at the injection site, or mild systemic reactions, such as headache, nausea, abdominal pain, muscle aches, and dizziness. Approximately 6% of persons receiving booster vaccinations with HDCV can experience an immune complex-like reaction characterized by urticaria, pruritus, and malaise. Once initiated, rabies postexposure prophylaxis should not be interrupted or discontinued because of local or mild systemic reactions to rabies vaccine.

Precautions and Contraindications

Pregnancy. Pregnancy is not a contraindication to postexposure prophylaxis.

Age. In infants and children, the dose of HDCV, PCEC, or RVA for preexposure or postexposure prophylaxis is the same as that recommended for adults. The dose of RIG for postexposure prophylaxis is based on body weight (Table 3–16).

For more information about rabies, see the CDC rabies site at http://www.cdc.gov/ncidod/dvrd/rabies

— Charles Rupprecht


 Top of Page


Travelers' Health Home | Contact Us |

CDC Home | Search | Health Topics A-Z |

This page last reviewed April 12, 2004

Division of Global Migration and Quarantine |
National Center for Infectious Diseases |
Centers for Disease Control and Prevention |

CDC Privacy Policy | Accessibility |
 

Travelers' Health Home Contact Us Mexico and Central America Caribbean Tropical South America Temperate South America Western Europe Eastern Europe and the Newly Independent States of the former Soviet Union (NIS) Middle East North Africa West Africa East Africa Australia and the South Pacific East Asia Southeast Asia Central Africa Southern Africa Indian Subcontinent North America